However, the SHARP trial showed a trend towards benefit in atherosclerotic events, and post hoc analyses of AURORA and 4-D showed benefits among diabetic patients and among those with an LDL concentration greater than 145 mg/dL.
← all excerpts
Coronary artery disease in patients with chronic kidney disease: a clinical update.
1
—
—